EMD SERONO

EMD SERONO

approved_indications FDA Approved Biologics and Pending Applications


Bavencio®

avelumab
BL 761049 / BL 761078

Gonal-f®

follitropin alfa/beta
BL 020378

Gonal-f® RFF

follitropin alfa/beta
BL 021765

Gonal-f® RFF Redi-ject®

follitropin alfa/beta
BL 021684

Ovidrel®

chorigonadotropin alfa
BL 021149

Rebif®

interferon beta-1a
BL 103780

Saizen®

somatropin
BL 019764

Serostim®

somatropin
BL 020604

Zorbtive®

somatropin recombinant
BL 021597

approved_indications U.S. Patent Litigations


AVONEX / BETASERON / EXTAVIA / REBIF2:10-cv-02734 (D.N.J.)
2:10-cv-02760 (D.N.J.)
OPDIVO / BAVENCIO1:17-cv-01029 (D. Del.)

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha